Abstract
Background and basis: Currently, there is no specific treatment option for the pulmonary hypertensive complication in patients with chronic left heart failure. Many studies have shown that prolonged use of sildenafil can reduce pulmonary artery pressure in this patient population. Subjects and Methods: 61 patients with chronic left heart failure with pulmonary hypertension, receiving medical treatment according to the standard therapy, were randomized into 2 groups: the sildenafil group (sildenafil was added, average dose of 50 mg/day) and the control group (no sildenafil). Results: After 4 weeks of treatment, the rate of NYHA IV, Minnesota quality of life score, 6-minute walk distance and mean pulmonary artery pressure (mPAP) of the sildenafil group significantly improved from baseline (-15%, -19, +11 m, -9 mmHg, respectively, p<0.01), and significantly improved compared to the control group (-15% vs -9%, -19 vs -10, +11 m vs +7 m, -9 mmHg vs -2 mmHg, respectively, p<0.01). Conclusions: Sildenafil was well tolerated; it may be an appropriate treatment option for patients with left heart failure who develop secondary pulmonary hypertension.